Greenyn Biotechnology Co., Ltd

6846 · TWO · Healthcare / Biotechnology

50.10TWD-0.40 (-0.79%)

Price History

Full chart

Market Stats

Previous Close50.50

Open49.05

Day Range48.70 – 50.10

52-Week Range55.60 – 73.41

Volume4.04K

Market Cap1.58B

P/E (TTM)15.12

Forward P/E0.00

EPS3.87

Dividend Yield6.74%

50-Day Avg58.91

200-Day Avg67.38

About

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Bang-Kui Xu
Employees0
HeadquartersNo. 43, Keya Road, Taichung, Taiwan, 428, Taiwan
Websitehttps://www.greenynbio.com

Leadership

Mr. Bang-Kui XuPresident, GM, Head of Sales Departments 1 & 2 & Director
Mr. Yan-Qin HuangVice Chairman & VP of Operations

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	693.77M	705.31M	800.51M	873.24M	915.32M
Growth (%)	-	+1.66%	+13.50%	+9.09%	+4.82%
Cost of Revenue	335.75M	334.38M	408.05M	458.01M	475.28M
Gross Profit	358.02M	370.93M	392.46M	415.23M	440.04M
Gross Margin	51.61%	52.59%	49.03%	47.55%	48.07%
Operating Expense	188.89M	204.24M	231.61M	247.37M	251.23M
Operating Income	169.13M	166.69M	160.85M	167.86M	188.81M
Operating Margin	24.38%	23.63%	20.09%	19.22%	20.63%
EBITDA	-	210.40M	192.40M	215.81M	232.38M
EBITDA Margin	-	29.83%	24.03%	24.71%	25.39%
Net Income	132.78M	146.74M	130.66M	146.00M	145.52M
Net Income Margin	19.14%	20.80%	16.32%	16.72%	15.90%
R&D	52.46M	57.43M	56.25M	55.61M	47.62M
R&D as % of Total Revenue	7.56%	8.14%	7.03%	6.37%	5.20%
Interest Expense	1.37M	1.25M	1.65M	1.50M	11.97M
Interest Expense % of Total Revenue	0.20%	0.18%	0.21%	0.17%	1.31%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	844.86M	834.81M	1.16B	1.11B	2.11B
Total Liabilities	231.09M	272.80M	364.48M	257.32M	1.13B
Total Equity	613.76M	562.01M	796.91M	851.35M	978.56M
Cash	356.13M	370.30M	533.51M	552.38M	793.36M
Net Debt	-	-	-	-	69.52M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	81.79M	229.73M	127.10M	219.66M	158.90M
Capital Expenditure	17.74M	17.14M	89.37M	9.78M	395.08M
Free Cash Flow	64.05M	212.59M	37.73M	209.89M	-236.18M
Dividends Paid	48.30M	200.19M	95.21M	93.92M	97.14M
FCF to OCF	78.31%	92.54%	29.69%	95.55%	-148.63%
Dividend Paid to FCF	75.41%	94.17%	252.34%	44.75%	-41.13%

Earnings

Report Date	Nov 13, 2024
EPS Estimate	1.06
EPS Actual	1.07
Surprise	0.94%
Timing	After-hours

Key Statistics & Ratios

Market Cap1.58B

Enterprise Value1.61B

Trailing P/E15.12

Forward P/E0.00

Price / Sales1.82

Price / Book1.72

EPS3.87

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity0.00%

Return on Assets0.00%

Shares Outstanding27.07M

Shares Float0

Dividend Yield6.74%

Dividend Rate3.94

Payout Ratio101.94%

Dividends

20261×

3.94Jun 25, 2026

20251×

3.60Mar 26, 2025

20241×

3.50May 27, 2024

20231×

3.90Mar 30, 2023